Australia passes off-patent drugs price cut bill
This article was originally published in Scrip
Australia's parliament passed its medicines bill this week, bringing price disclosures and weighted average price cuts of 23% for off-patent and generic medicines for the state funded Pharmaceutical Benefits Scheme (PBS). The passage was welcomed by the industry association Medicines Australia which had wanted the bill to be passed this month as price disclosures are expected to start from 1 December (scripintelligence.com, 3 November 2010).
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.